Clinical and translational allergy · 2025
Sexual Health in Atopic Dermatitis: Impact of Skin Clinical Control.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sánchez Jorge, Montoya Gabriel, Caraballo Ana, Ordoñez-Rubiano María-Fernanda, Velasquez Margarita, Arenas Claudia, Londoño Julián, García Elizabeth
Аннотация
BACKGROUND: Sexual health in patients with atopic dermatitis (AD) remains scarcely studied. Identifying the problematic of sexual health disorders (SHD) in AD and associated factors is important for the design and implementation of targeted interventions.
OBJECTIVE: To describe the frequency of sexual health disorders (SHD) in AD patients, identify risk factors and assess whether improved AD control with pharmacotherapy is associated with changes in SHD.
METHODS: We performed a prospective observational study in AD patients over 18 years of age. Participants completed a survey assessing clinical aspects of SHD and AD at baseline and 5-7 months after initiating specialists-recommended treatment. For AD severity evaluation we used SCORAD and POEM scales and for SHD we used SyDSF-AP, IFSF, and MGH-SFQ.
RESULTS: A total of 221 AD patients were enrolled. At baseline, the frequency of SHD varied according to AD severity (SHD in severe AD 100%, in moderate AD 96%, and in mild AD 56%). Risk factors for SHD were AD severity (SCORAD OR 3.88 [95% CI 2.68-4.73], POEM OR 4.67 [95% CI 3.05-5.79]), skin area affected (OR 3.15 [95% CI 2.88-5.19]), and disease duration (OR 3.75 [95% CI 1.88-4.91]). Improved AD control through pharmacotherapy reduced SHD frequency in mild AD (relative reduction [RR]: -60%), moderate AD (RR: -41%), and severe AD (RR: -28%).
CONCLUSION: Atopic dermatitis was frequently associated with SHD even in mild forms of the disease. However, AD clinical control reduced the frequency of SHD, and consequently improving the quality of life of patients.
OBJECTIVE: To describe the frequency of sexual health disorders (SHD) in AD patients, identify risk factors and assess whether improved AD control with pharmacotherapy is associated with changes in SHD.
METHODS: We performed a prospective observational study in AD patients over 18 years of age. Participants completed a survey assessing clinical aspects of SHD and AD at baseline and 5-7 months after initiating specialists-recommended treatment. For AD severity evaluation we used SCORAD and POEM scales and for SHD we used SyDSF-AP, IFSF, and MGH-SFQ.
RESULTS: A total of 221 AD patients were enrolled. At baseline, the frequency of SHD varied according to AD severity (SHD in severe AD 100%, in moderate AD 96%, and in mild AD 56%). Risk factors for SHD were AD severity (SCORAD OR 3.88 [95% CI 2.68-4.73], POEM OR 4.67 [95% CI 3.05-5.79]), skin area affected (OR 3.15 [95% CI 2.88-5.19]), and disease duration (OR 3.75 [95% CI 1.88-4.91]). Improved AD control through pharmacotherapy reduced SHD frequency in mild AD (relative reduction [RR]: -60%), moderate AD (RR: -41%), and severe AD (RR: -28%).
CONCLUSION: Atopic dermatitis was frequently associated with SHD even in mild forms of the disease. However, AD clinical control reduced the frequency of SHD, and consequently improving the quality of life of patients.